Deutsche Bank raised the firm’s price target on Sutro Biopharma (STRO) to $51 from $5 and keeps a Buy rating on the shares. The company’s STRO-004 is entering the Clinic while its dual payload antibody-drug conjugates will emerge in 2026, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STRO:
- Sutro Biopharma’s Promising Phase 1 Study on STRO-004: A Potential Game-Changer in Cancer Treatment
- Vanguard Total Stock Market ETF (VTI) Daily Update—12/04/25
- Sutro Biopharma Announces Reverse Stock Split
- Sutro Biopharma announces first cohort dosed in Phase 1 trial of STRO-004
- Sutro Biopharma trading halted, news pending